This review examines the practice of excluding smokers with MHDs and reasons for such exclusion in clinical trials evaluating pharmacotherapy treatments for smoking cessation.
This article outlines the experiences of a postgraduate student conducting research on drug use and ‘wild self-care’ in the format of a dialogue with their supervisor.
Oral health related quality of life is known to be reduced in disadvantaged populations, including people who inject drugs. Mental health issues, such as depression are also commonly reported.
In 2020, the WA Ecstasy and related Drugs Reporting System (EDRS) documented record highs in self-reported recent use of cocaine, ketamine, amyl nitrite (‘poppers’) and nitrous oxide (‘nangs’). While these substances are commonly perceived as relatively harmless ‘party drugs’, and are on the mid to lower end of harm ranking systems, use still carries risks.